DOP2019000204A - Dendrímeros terapéuticos - Google Patents
Dendrímeros terapéuticosInfo
- Publication number
- DOP2019000204A DOP2019000204A DO2019000204A DO2019000204A DOP2019000204A DO P2019000204 A DOP2019000204 A DO P2019000204A DO 2019000204 A DO2019000204 A DO 2019000204A DO 2019000204 A DO2019000204 A DO 2019000204A DO P2019000204 A DOP2019000204 A DO P2019000204A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- dendrimers
- therapeutic
- formula
- disclosed
- dendrimer
- Prior art date
Links
- 239000000412 dendrimer Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229920000736 dendritic polymer Polymers 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/40—Polyamides containing oxygen in the form of ether groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se divulgan dendrímeros de fórmula (I): (I) y sales farmacéuticamente aceptables de los mismos. También se divulgan composiciones farmacéuticas que comprenden el dendrímero de fórmula (I) y métodos para usar los mismos para el tratamiento del cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762461983P | 2017-02-22 | 2017-02-22 | |
US201762488151P | 2017-04-21 | 2017-04-21 | |
US201762591823P | 2017-11-29 | 2017-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2019000204A true DOP2019000204A (es) | 2019-08-30 |
Family
ID=61386833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2019000204A DOP2019000204A (es) | 2017-02-22 | 2019-08-08 | Dendrímeros terapéuticos |
Country Status (23)
Country | Link |
---|---|
US (4) | US10314920B2 (es) |
EP (1) | EP3585441A1 (es) |
JP (1) | JP7074761B2 (es) |
KR (2) | KR20230093346A (es) |
CN (2) | CN110312531A (es) |
AU (1) | AU2018223149B2 (es) |
BR (1) | BR112019016409A2 (es) |
CA (1) | CA3053069A1 (es) |
CL (1) | CL2019002240A1 (es) |
CO (1) | CO2019009722A2 (es) |
CR (1) | CR20190361A (es) |
DO (1) | DOP2019000204A (es) |
EC (1) | ECSP19056271A (es) |
IL (1) | IL268648B (es) |
JO (1) | JOP20190191A1 (es) |
MX (1) | MX2019009442A (es) |
NI (1) | NI201900088A (es) |
PE (1) | PE20191660A1 (es) |
PH (1) | PH12019501896A1 (es) |
SG (1) | SG11201907334QA (es) |
TW (1) | TWI773730B (es) |
UA (1) | UA125655C2 (es) |
WO (1) | WO2018154004A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
TW202021575A (zh) * | 2018-08-17 | 2020-06-16 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
EP4034169A4 (en) * | 2019-09-26 | 2023-11-01 | Starpharma Pty Limited | THERAPEUTIC DENDRIMER |
CA3163886A1 (en) * | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery |
US11931418B2 (en) | 2020-04-24 | 2024-03-19 | Ashvattha Therapeutics, Inc. | Methods of treating severe inflammation |
WO2021213492A1 (zh) * | 2020-04-24 | 2021-10-28 | 上海森辉医药有限公司 | 一类载药的大分子及其制备方法 |
JP2023533735A (ja) * | 2020-07-10 | 2023-08-04 | 江蘇恒瑞医薬股▲ふん▼有限公司 | スルホニルベンズアミド系誘導体及びその複合体、その調製方法並びにその応用 |
CA3190406A1 (en) | 2020-08-25 | 2022-03-03 | Jian Huang | Drug-loaded macromolecule and preparation method therefor |
WO2022040761A1 (en) * | 2020-08-31 | 2022-03-03 | Starpharma Pty Ltd | Dendrimer-drug conjugate |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4289872A (en) * | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
US4410688A (en) * | 1981-04-29 | 1983-10-18 | Allied Corporation | Macromolecular highly branched homogeneous compound |
US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
NZ561609A (en) | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
HUE031341T2 (hu) * | 2005-10-25 | 2017-07-28 | Starpharma Pty Ltd | Ellenõrzött sztöchiometriájú makromolekuláris vegyületek |
AU2006336176B2 (en) | 2006-01-20 | 2013-08-22 | Starpharma Pty Limited | Modified macromolecule |
EP2076557A4 (en) * | 2006-08-11 | 2012-08-29 | Starpharma Pty Ltd | POLYLYSINE DENDRIMER CONTRAST AGENT |
CN101516969B (zh) * | 2006-08-11 | 2013-07-03 | 星药股份有限公司 | 靶向的聚赖氨酸树状聚体治疗剂改性的大分子2 |
NZ577442A (en) | 2006-11-15 | 2012-02-24 | Genentech Inc | Arylsulfonamide compounds |
US9283302B2 (en) | 2011-12-16 | 2016-03-15 | Cormatrix Cardiovascular, Inc. | Extracellular matrix encasement structures and methods |
WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
CN102076331B (zh) | 2008-06-26 | 2013-12-18 | 普罗林科斯有限责任公司 | 具有可控的药物释放速率的前药和药物-大分子轭合物 |
US8216549B2 (en) * | 2008-07-25 | 2012-07-10 | National Health Research Institutes | Method for making a ligand-quantum dot conjugate |
CA2744711C (en) | 2008-12-05 | 2017-06-27 | Abbott Laboratories | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
ME02205B (me) | 2009-05-26 | 2016-02-20 | Abbvie Bahamas Ltd | INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
US20120269721A1 (en) * | 2009-10-12 | 2012-10-25 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
EP2571496A4 (en) | 2010-05-05 | 2016-03-30 | Prolynx Llc | CONTROLLED RELEASE OF MEDICINE FROM DENIMERS |
WO2011140393A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled release from macromolecular conjugates |
WO2011140392A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from solid supports |
TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
WO2012167309A1 (en) * | 2011-06-06 | 2012-12-13 | Starpharma Pty Ltd | Macromolecules |
US20160220689A1 (en) * | 2013-09-10 | 2016-08-04 | Starpharma Pty Ltd. | Macromolecules of dendrimer-platinum conjugates |
EP3152248B1 (en) * | 2014-06-06 | 2019-10-09 | Starpharma Pty Ltd | Dendrimer-drug conjugates |
JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
TW202021575A (zh) * | 2018-08-17 | 2020-06-16 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
-
2017
- 2017-06-16 JO JOP/2019/0191A patent/JOP20190191A1/ar unknown
-
2018
- 2018-02-12 TW TW107105033A patent/TWI773730B/zh active
- 2018-02-20 US US15/899,892 patent/US10314920B2/en active Active
- 2018-02-22 CN CN201880012429.9A patent/CN110312531A/zh active Pending
- 2018-02-22 BR BR112019016409A patent/BR112019016409A2/pt unknown
- 2018-02-22 WO PCT/EP2018/054420 patent/WO2018154004A1/en unknown
- 2018-02-22 CR CR20190361A patent/CR20190361A/es unknown
- 2018-02-22 CN CN202311534590.1A patent/CN117582521A/zh active Pending
- 2018-02-22 KR KR1020237019533A patent/KR20230093346A/ko active IP Right Grant
- 2018-02-22 SG SG11201907334QA patent/SG11201907334QA/en unknown
- 2018-02-22 CA CA3053069A patent/CA3053069A1/en active Pending
- 2018-02-22 KR KR1020197027415A patent/KR102544033B1/ko active IP Right Grant
- 2018-02-22 UA UAA201909735A patent/UA125655C2/uk unknown
- 2018-02-22 AU AU2018223149A patent/AU2018223149B2/en active Active
- 2018-02-22 EP EP18707681.5A patent/EP3585441A1/en active Pending
- 2018-02-22 MX MX2019009442A patent/MX2019009442A/es unknown
- 2018-02-22 PE PE2019001564A patent/PE20191660A1/es unknown
- 2018-02-22 JP JP2019543376A patent/JP7074761B2/ja active Active
-
2019
- 2019-04-05 US US16/376,419 patent/US10888624B2/en active Active
- 2019-08-06 EC ECSENADI201956271A patent/ECSP19056271A/es unknown
- 2019-08-08 CL CL2019002240A patent/CL2019002240A1/es unknown
- 2019-08-08 DO DO2019000204A patent/DOP2019000204A/es unknown
- 2019-08-12 IL IL268648A patent/IL268648B/en unknown
- 2019-08-15 PH PH12019501896A patent/PH12019501896A1/en unknown
- 2019-08-20 NI NI201900088A patent/NI201900088A/es unknown
- 2019-09-09 CO CONC2019/0009722A patent/CO2019009722A2/es unknown
-
2020
- 2020-11-11 US US17/095,043 patent/US11717574B2/en active Active
-
2023
- 2023-06-14 US US18/334,672 patent/US20240115716A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019009722A2 (es) | Dendrímeros terapéuticos | |
CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
NI201900062A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CL2020002511A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
UY37205A (es) | Inhibidores de bromodominios | |
CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
AR111063A1 (es) | Dendrímeros terapéuticos | |
EA201991924A1 (ru) | Терапевтические дендримеры | |
CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |